Speciality Medicines
SPECIALITYMEDICINESLTD NSE
Speciality Medicines
NSE: SPECIALITYMEDICINESLTD BSE: SPML
Key Fundamentals
SMEMarket Cap
₹153 Cr
Volatility
Moderate
P/E Ratio
10.7
EBITDA
₹13.69 Cr
Return on Equity
28.3%
Debt to Equity
0.1
Book Value
₹81.04
52W High
₹381.2
52W Low
₹121.1
Tapetide Score
Data-driven rating, 0–100. How it works →
Growth Rate
Revenue Growth
28.7% lower than
3Y
Net Income Growth
51.4% lower than
3Y
Cash Flow Change
-20.63% higher than
3Y
ROE
45.35% higher than
3Y
ROCE
-14.57% higher than
3Y
EBITDA Margin (Avg.)
12.45% higher than
3Y
Quarterly Results
| Particulars | Mar 2025 | Mar 2026 |
|---|---|---|
| Sales | 31 | 45 |
| Expenses | 26 | 36 |
| Operating Profit | 4 | 8 |
| OPM % | 14% | 19% |
| Other Income | 0 | 1 |
| Interest | 0 | 1 |
| Depreciation | 0 | 0 |
| PBT | 4 | 8 |
| Tax % | 36% | -1% |
| Net Profit | 3 | 8 |
| EPS in Rs | 4.16 | 9.31 |
Profit & Loss
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 40 | 23 | 28 | 58 | 75 |
| Expenses | 38 | 20 | 22 | 49 | 62 |
| Operating Profit | 2 | 4 | 5 | 9 | 14 |
| OPM % | 6% | 15% | 19% | 16% | 18% |
| Other Income | 0 | 0 | 0 | 0 | 1 |
| Interest | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 |
| PBT | 2 | 3 | 5 | 9 | 13 |
| Tax % | 31% | 43% | 36% | 1% | 0% |
| Net Profit | 1 | 2 | 3 | 9 | 13 |
| EPS in Rs | 70.48 | 4.42 | 5.73 | 13.38 | 14.83 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity Capital | 0.21 | 4 | 5 | 6 | 9 |
| Reserves | 2 | 2 | 10 | 24 | 62 |
| Borrowings | 1 | 4 | 3 | 5 | 7 |
| Other Liabilities | 3 | 4 | 5 | 5 | 17 |
| Total Liabilities | 6 | 13 | 23 | 40 | 95 |
| Fixed Assets | 2 | 2 | 1 | 2 | 2 |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 4 | 11 | 21 | 38 | 93 |
| Total Assets | 6 | 13 | 23 | 40 | 95 |
Cash Flow
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating | 1 | -4 | -5 | -6 | -1 |
| Investing | -2 | 0 | 0 | -2 | -3 |
| Financing | 2 | 4 | 5 | 8 | 28 |
| Net Cash Flow | 0 | 0 | 0 | 1 | 24 |
| Free Cash Flow | -1 | -4 | -5 | -6 | -1 |
| CFO/OP | 36 | -101 | -66 | -63 | -9 |
Ratios
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debtor Days | 23 | 87 | 142 | 60 | 128 |
| Inventory Days | 5 | 103 | 161 | 150 | 191 |
| Days Payable | 12 | 40 | 48 | 8 | 80 |
| Cash Conversion Cycle | 16 | 149 | 255 | 202 | 239 |
| Working Capital Days | -3 | 76 | 185 | 180 | 221 |
| ROCE % | — | 52% | 38% | 34% | 25% |
Documents
1
Board Meeting Outcome for Outcome Of Board Meeting Held On April 28 2026
28 Apr - Board appointed secretarial and internal auditors; authorised KMP and reviewed related party transactions. 28 Apr - Board appointed secretarial and internal auditors; authorised KMP and reviewed related party transactions.
2
Announcement under Regulation 30 (LODR)-Change in Management
28 Apr - Board met on 28 April 2026, appointed secretarial and internal auditors, and authorised KMP for disclosures. 28 Apr - Board met on 28 April 2026, appointed secretarial and internal auditors, and authorised KMP for disclosures.
3
Intimation Of Contact Details Of Key Managerial Personnel Pursuant To Regulation 30(5) Of SEBI (LODR) Regulations 2015
28 Apr - Company disclosed KMP contact details for Regulation 30(5) and uploaded them on website. 28 Apr - Company disclosed KMP contact details for Regulation 30(5) and uploaded them on website.
4
Board Meeting Outcome for Outcome Of Board Meeting Held On April 28 2026
28 Apr - Board appointed secretarial and internal auditors; authorised KMP and reviewed related party transactions. 28 Apr - Board appointed secretarial and internal auditors; authorised KMP and reviewed related party transactions.
5
Announcement under Regulation 30 (LODR)-Change in Management
28 Apr - Board met on 28 April 2026, appointed secretarial and internal auditors, and authorised KMP for disclosures. 28 Apr - Board met on 28 April 2026, appointed secretarial and internal auditors, and authorised KMP for disclosures.
Frequently Asked Questions about Speciality Medicines
Where is Speciality Medicines (SPML) listed?
Speciality Medicines trades as SPECIALITYMEDICINESLTD on the NSE and under code SPML on the BSE.
What is the market capitalisation of Speciality Medicines?
Speciality Medicines has a market capitalisation of ₹152.76 Cr, which places it in the Small Cap band.
What is the PE ratio of Speciality Medicines?
Speciality Medicines trades at a PE ratio of 10.70, against a book value of ₹81.04 per share.
What is the 52-week high and low of Speciality Medicines?
Over the last 52 weeks Speciality Medicines has traded between ₹121.1 and ₹381.2.
What is the Return on Equity (ROE) of Speciality Medicines?
Speciality Medicines reported a return on equity of 28.30%. Its debt-to-equity ratio is 0.10.
Company Information
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SPML.md for Speciality Medicines: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.